Seattle Genetics Outlines Plans to Hire More Employees and Boost its Drug Pipeline

Earlier this year, the Seattle Genetics made indications regarding its drug pipeline and employee status. According to Clay Siegall, Seattle Genetics Chief Executive Officer, the company was undertaking various tests of its first and only commercialized drug dubbed Adcetris in a wide range of cancer treatment situations. As such, he revealed that the drug was being tested in over 70 trials against different kinds of lymphomas.

The statement given by Clay Siegall revealed that Seattle Genetics was undertaking a Phase 3, advanced clinical trial. The Phase 3 Trials included Adcetris as the primary treatment for formerly untreated as well as newly detected Hodgkin Lymphoma. Apart from Adcetris, Seattle Genetics hopes to develop 12 new drugs. In such effort, it revealed plans to develop two drugs to treat bladder cancer, one to cure breast cancer and another to cure acute myeloid leukemia. Apart from the drug addition, Clay gave an insight into Seattle Genetics’ plans to hire a hundred more employees in the United States as well as 20 in Switzerland by the end of 2016.

Adcetris

Adcetris, a lymphomas fighting drug, ranks up as one of the major milestones of Seattle Genetics. Last year, it garnered $226 million in terms of sales in both Canada and the United States. The company leverages the role played by its partner company, Takeda Pharmaceuticals, in selling Adcetris outside Canada and the United States.

A Detailed Look at Seattle Genetics and CEO Clay Siegall

Seattle Genetics boasts as one of the top biotechnology companies in the world, which specializes in creating and commercializing antibody-based therapies for curing cancer. Its treatment takes advantage of the ability of antibody-drug conjugates to kill cancer cells without harming non-targeted cells. Clay Siegall is given credit for the accomplishments attained by Seattle Genetics, as he is the Chairperson and CEO of the company. Having worked for various companies such as Bristol-Myers Squibb Pharmaceutical Research Institutes and the National Institutes of Health, he is a man of vast experience.

Sources:

http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS-Interview-Siegall.pdf

http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html